Table 3

Patient demographics and characteristics at baseline

All patients
N=1485
Diabetes specialist n=617Non-specialist n=868
Age (years), mean (SD)59.7 (13.3)55.6 (12.8)62.7 (12.8)
Female, n (%)567 (38.2)226 (36.6)341 (39.3)
BMI (kg/m2), median (IQR)25.5 (23.0‒28.6)25.6 (23.0‒28.8)25.4 (23.0‒28.6)
 ≥25, n (%)813 (54.7)345 (55.9)468 (53.9)
Disease duration (years), mean (SD)0.9 (1.9)0.8 (1.8)0.9 (1.9)
Baseline HbA1c (%), mean (SD)8.1 (1.9)8.4 (1.9)7.9 (1.8)
Target HbA1c (%), mean (SD)6.5 (0.5)6.7 (0.6)6.4 (0.4)
Classification in CKD stage by eGFR, n (%), n=1250*
 G1369 (29.5)199 (39.3)170 (22.8)
 G2687 (55.0)255 (50.4)432 (58.1)
 G3a143 (11.4)46 (9.1)97 (13.0)
 G3b36 (2.9)5 (1.0)31 (4.2)
 G411 (0.9)1 (0.2)10 (1.3)
 G54 (0.3)0 (0.0)4 (0.5)
Diabetic complications, n (%)196 (13.2)123 (19.9)73 (8.4)
Cardiovascular disease, n (%)91 (6.1)14 (2.3)77 (8.9)
Dyslipidemia, n (%)856 (57.6)300 (48.6)556 (64.1)
Hypertension, n (%)760 (51.2)234 (37.9)526 (60.6)
  • *Number of patients with available eGFR data.

  • BMI, body mass index; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin.